期刊文献+

孕激素及其受体与蜕膜化 被引量:3

Association between Decidualization and Progesterone&Its Receptors
下载PDF
导出
摘要 蜕膜化过程精密且复杂,受到激素、细胞和分子信号之间微妙的相互作用。孕激素是调控蜕膜化和胚胎着床的主要调节因子,在子宫内膜蜕膜化过程中起主导地位。在月经周期分泌晚期(月经周期的第24~28天),孕激素(progestogen)结合孕激素受体(progesterone receptor,PR)刺激子宫内膜蜕膜化标志物催乳素(prolactin,PRL)的合成,介导蜕膜化的发生。在复杂的蜕膜化机制中,孕激素与PR主要为控制上皮细胞增殖获得子宫容受性和刺激基质细胞分化建立妊娠。在流产疾病中,妊娠孕激素及孕激素受体的监测对预测妊娠早期胚胎丢失具有指导意义。本文对孕激素和PR在狭义蜕膜化中的作用及其机制进行综述。 Decidualization is a delicate and complex process,which is regulated by hormones and cellular and molecular signals.Progesterone plays a leading role in the process of decidualization and embryo implantation.In the late period of menstrual cycle(the day 24-28 of menstrual cycle),the progesterone combined with progesterone receptor(PR)stimulates the synthesis of prolactin(PRL),a marker of endometrium decidualization,and mediates the occurrence of decidualization.In the complex mechanism of decidualization,progesterone and PR are mainly to control the epithelial cell proliferation to obtain uterine receptivity,and to stimulate stromal cell differentiation to establish pregnancy.The monitoring of progesterone and progesterone receptor has a guiding significance for the prediction of early embryo loss in those patients with habitual abortion.The role of progesterone and PR and the mechanism in decidualization were reviewed in this paper.
作者 蒋莎 陈璐 王炜 常卓 张杨 冯晓玲(审校) JIANG Sha;CHEN Lu;WANG Wei;CHANG Zhuo;ZHANG Yang;FENG Xiao-ling(Heilongjiang University of Chinese Medicine,Harbin 150040,China;The First Affiliated Hospital of Heilongjiang University of Chinese Medicine,Harbin 150040,China)
出处 《国际生殖健康/计划生育杂志》 CAS 2020年第6期495-498,共4页 Journal of International Reproductive Health/Family Planning
基金 国家自然科学基金(81973894,81574014) 黑龙江中医药大学“优秀创新人才支持计划”(2018RCL12)。
关键词 孕激素类 受体 孕酮 子宫内膜 蜕膜 蜕膜化 Progestins Receptors,progesterone Endometrium Decidua Decidualization
  • 相关文献

参考文献2

二级参考文献13

  • 1Csapo AI, Pulkkinen MO, Ruttner B, et al. The significance of the human corpus lutenm in pregnancy maintenance. I. Preliminary studies[J]. Am J Obstet Gynecol, 1972, 112(8): 1061-1067.
  • 2Wahabi HA, Fayed AA, Esmaeil SA, et al. Progestogen for treating threatened miscarriage[J]. Cochrane Database Syst Rev, 2011(12):CD005943. DOI: 10.1002/14651858.CD005943. pub4.
  • 3Schindler AE, Carp H, Druckmann R, et al. European Progestin Club Guidelines for prevention and treatment of threatened or recurrent (habitual) miscarriage with progestogens[J]. Gyneeol Endocrinol, 2015, 31(6):447-449. DOI: 10.3109/09513590.2015.1017459.
  • 4Kumar A, Begum N, Prasad S, et al. Oral dydrogesterone treatment during early pregnancy to prevent recurrentpregnancy loss and its role in modulation of cytokine production: a double-blind, randomized, parallel, placebo- controlledtrial[J]. Fertil Steril, 2014, 102(5):1357-1363.e3. DOI: 10.1016/j.fertnstert.2014.07.1251.
  • 5Coomarasamy A, Williams H, Truchanowicz E, et al. A Randomized Trial of Progesterone in Women with Recurrent Miscarriages[J]. N Engl J Med, 2015, 373(22):2141-2148. DOI: 10.1056/NEJMoa1504927.
  • 6Haas DM, Ramsey PS. Progestogen for preventing miscarriage [J]. Cochrane Database Syst Rev, 2013(10):CD003511. DOI: 10.1002/14651858.CD003511 .pub3.
  • 7Lira CE, Ho KK, Cheng NC, et al. Combined oestrogen and progesterone for preventing miscarriage[J]. Cochrane Database Syst Rev, 2013(~9):CD009278. DOI: 10.1002/14651858. CD009278.pub2.
  • 8Szekeres-Bartho J, Balasch J. Progestagen therapy for recurrent miscarriage[J]. Hum Reprod Update, 2008,14(1): 27-35. DOI: lO.1093/humupd/dmm035.
  • 9Fatemi HM. The luteal phase after 3 decades of IVF: what do we know?[J]. Reprod Biomed Online, 2009,19 Suppl 4:4331.
  • 10Hughes GC. Progesterone and autoimmune disease[J]. Autoimmun Rev, 2012, 11(6-7):A502-514. DOh 10.1016/j. autrev.2011.12.003.

共引文献69

同被引文献47

引证文献3

二级引证文献3

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部